Please assess the completion status of the following clinical trial:

Trial Title: 12-Week Study of Plecanatide for CIC (The National CIC3 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-80, inclusive~* Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months~* Completed a colonoscopy in accordance with American Gastroenterological Association (AGA) colon cancer screening guidelines (5 years), with no clinically significant findings~* Willing to maintain a stable diet during the study~Exclusion Criteria:~* Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for \> 25% of Bowel Movements (BMs) during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment~* Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable~* History of cathartic colon, laxative, enema abuse, or ischemic colitis~* Fecal impaction within 3 months of screening~* Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain~* Unexplained and clinically significant alarm symptoms including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis~* Major surgery, stroke or myocardial infarction (MI) within 60 days of screening~* Participated in a previous plecanatide clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Plecanatide 3.0 mg (Type: EXPERIMENTAL): Plecanatide tablets 3.0 mg QD for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets QD for 12 weeks
- Plecanatide 6.0 mg (Type: EXPERIMENTAL): Plecanatide tablets 6.0 mg QD for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).